CAD-1883, a first-in-class selective positive allosteric modulator of SK channels (small conductance, calcium-activated potassium ion channels) was discovered in a research collaboration between Saniona and Cadent Therapeutics. By increasing the calcium sensitivity of the SK channels, CAD-1883 causes potassium current to flow at lower calcium concentrations, potentially restoring neuronal firing regularity and improving motor function.
Cadent Therapeutics is currently developing CAD-1883 for treatment of the neurological movement disorders, essential tremor and spinocerebellar ataxia. CAD-1883 has, in a Phase 1 dose escalation trial, been well-tolerated at all doses to date. In addition to ownership in the merged Cadent Therapeutics, Saniona is also eligible to receive royalties on any potential products developed and commercialized from the collaboration program.
Essential tremor is a neurological disorder characterized by uncontrollable shaking or tremor in different parts of the body, including the head, arms, hands, neck, and chin. It is the most common movement disorder affecting 10 million people in the United States alone. In preclinical disease models, CAD-1883 has demonstrated the ability to improve motor control and reduce tremor. A Phase 2 trial was initiated in the fourth quarter of 2018 for the treatment of essential tremor.
Spinocerebellar ataxia is a genetic, degenerative neurological condition that affects approximately 6,000 people in the United States. Patients are readily identified through genetic testing and most often carry genetic abnormalities called “poly-Q expansions,” similar to those found in patients with Huntington’s disease. The disease is progressive and over time results in ongoing damage to the cerebellum, the part of the brain that regulates motor control and balance. The plan is to progress CAD-1883 into a Phase 2 trial for treatment of spinocerebellar ataxia in the second half of 2019.
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore motor and cognitive function in patients with serious neurological disease. The company leverages its unique precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Currently in early clinical development, Cadent Therapeutics is rapidly advancing its pipeline of therapies to treat spinocerebellar ataxia, essential tremor and schizophrenia. Investors include Atlas Venture, Clal Biotechnology Industries, Slater Technology Fund and Novartis.